Loading...
•
Mar 31, 2020
uniQure Q1 2020 Earnings Report
uniQure reported financial results for the first quarter of 2020 and highlighted recent progress across its business.
Key Takeaways
uniQure ended the first quarter of 2020 in a position of strength with cash and cash equivalents of $342.0 million. The company reported revenue of $0.1 million and a net loss of $28.0 million, or $0.63 loss per share.
Completed target patient dosing in Phase III HOPE-B Trial of Etranacogene Dezaparvovec in Hemophilia B
Announced 22 Presentations at Upcoming ASGCT Virtual Annual Meeting
Cash and cash equivalents totaled $342.0 million as of March 31, 2020
The Company currently expects cash and cash equivalents will be sufficient to fund operations into 2022.
Revenue by Segment
Forward Guidance
uniQure expects to announce new clinical data and advancements from across the business in the second half of the year.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...